Neumora Therapeutics financials
$0.6776−2.05%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$241.2M | -$263.5M | -$252.1M |
| Net income | -$236.9M | -$243.8M | -$235.9M |
| Net margin | — | — | — |
| Diluted EPS | $-1.45 | $-1.53 | $-3.63 |
| EBITDA | -$240.9M | -$262.8M | -$255.2M |
| Operating cash flow | -$206.4M | -$182.9M | -$167.9M |
| Free cash flow | -$206.4M | -$182.9M | -$168.0M |
| Diluted shares | 163.4M | 159.4M | 65.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $182.5M | $142.1M | $374.0M |
| Short-term investments | $0.00 | $165.4M | $79.9M |
| Total debt | $54.5M | $0.00 | $0.00 |
| Total assets | $191.0M | $317.0M | $496.2M |
| Total liabilities | $87.2M | $29.9M | $27.1M |
| Shareholders' equity | $103.9M | $287.1M | $469.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology